STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference

New data on a competing drug’s surprising failure could be pivotal for the biotech company Andrew Joseph/STAT Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals, as the outlook wavers for its two ATTR-CM drugs because of a competing drug’s surprising failure in the same heart disease. Cardiologists and investors attending the ESC meeting will learn new details from AstraZeneca and Ionis Pharmaceuticals about why their rival drug, eplontersen, failed to significantly reduce the risk of cardiovascular deaths or recurrent events compared to a placebo. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.